Cronos Group Stock Price to Suffer an Earnings Restatement Penalty

Cronos Group stock price getting punished as management writes off large portions of the little revenue gains the company made in 2019.

| More on:
Shopping card with boxes labelled REITs, ETFs, Bonds, Stocks

Image source: Getty Images.

Cronos Group (TSX:CRON)(NASDAQ:CRON) stock price fell by 12% early on Wednesday to give up some of its near 13% gains on Tuesday after the marijuana firm said it will effect a 40% charge on its third quarter 2019 revenue and will make a similar adjustment in its restated Q1 2019 earnings results.

Cronos will reduce its first-quarter and third-quarter revenues by C$2.5 million and C$5.1 million, respectively. Q1 2019 revenues were C$6.47 million, while Q3 2019 sales were reported at C$12.70 million.

A significant write-off

The restatements will wipe off nearly 26% of the company’s reported revenue for the first nine months of last year. A similar charge could be made in the outstanding fourth-quarter earnings.

Management had stated earlier, after a delay in the release of the company’s annual financial results, that it had yet to determine a final position vis a vis revenues from bulk sales of cannabis and extracts.

A review of “several bulk resin purchases and sales of products through the wholesale channel and the appropriateness of the recognition of revenue from those transactions” was ongoing by the first week of March.

Why is Cronos Group restating earnings results?

As the investing public, we still don’t know what triggered a review of the firm’s revenue recognition policy concerning wholesale market deals — and why this is happening at this hour.

Perhaps there was a surge in product return notifications, which has already happened at many other industry firms. Aurora Cannabis and more recently at Canopy Growth are among the affected large pot growers.

I speculated earlier that the company’s reporting delays could have something to do with the firm’s accounting standards migration.

The company is moving from a principles based International Financial Reporting Standards (IFRS) to a generally prescriptive and rules-based U.S. Generally Accepted Accounting Principles (U.S. GAAP) financial reporting framework.

That said, I wouldn’t expect revenue recognition policies to differ much between IFRS and U.S. GAAP, even for agricultural and pharmaceutical business operators.

We have seen extensive efforts toward the convergence of these two frameworks for some years, with the former largely consuming the later.

A disappearing market segment?

The wholesale bulk cannabis market has proven to be a significant source of challenges for the nascent industry, yet it was a significant source of growth for Aurora in the early legalization days in 2019.

CRON “…has been conducting a review of certain bulk resin purchases and sales of products through the wholesale channel, and the restatement is being made to eliminate certain of these transactions through the wholesale channel,” the company’s latest statement reveals.

The company is going to treat some wholesale market deals by eliminating them, as if they never existed.

While this is good in the sense that the remaining sales are likely to be the more recurring ones as we project revenues into the future in our financial models, this also means that a whole revenue segment has become increasingly unreliable and must be treated with extreme caution.

The wholesale segment should naturally die as everyone has already ramped up production.

Foolish bottom line

Revenue growth at CRON hasn’t been spectacular since recreational market legalization in Canada, and a significant portion of the little that the company posted in sales is now being written off in earnings restatements. Investors should be disappointed.

That said, this company is promising to disrupt the nascent cannabis industry through innovative cannabinoid manufacturing. Its recently acquired subsidiary in the United States could improve its growth prospects.

Moreover, it has one of the strongest industry balance sheets, thanks to a C$2.4 billion Altria investment. This feature makes it one of the numbered pot firms to survive the ongoing market turmoil.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Cannabis Stocks

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Cannabis Stocks

Canopy Growth: Is There Budding Potential in the Cannabis Market?

Canopy Growth stock hit 52-week lows recently on news of needing to re-file on its BIoSteel business, so what now?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

What’s Happening With Cannabis Stocks in May 2023?

Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is…

Read more »

Cannabis smoke
Cannabis Stocks

Are Cannabis Stocks a Good Buy in May 2023?

If you're going to buy cannabis stocks, these are pretty much the only two I would consider. Even so, you…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Aurora Cannabis: Time to Light Up Your Portfolio?

Here's my take on whether Aurora Cannabis (TSX:ACB) is worth adding to a growth portfolio right now, given its growth…

Read more »

Target. Stand out from the crowd
Tech Stocks

These Undervalued TSX Stocks Are a Bargain in May 2023

If you're willing to bet on a rebound, these are the three TSX stocks I would consider first as they…

Read more »

A cannabis plant grows.
Cannabis Stocks

Tilray Stock Is Scraping 52-Week Lows: Will it Bottom Out Soon?

Tilray (TSX:TLRY) stock remains down 53% in the last year, but when will this company hit the bottom and start…

Read more »

Medicinal research is conducted on cannabis.
Metals and Mining Stocks

2 Canadian Stocks That Are Simply Too Cheap to Avoid

These two Canadian stocks have sunk lower and lower, which is why now could be the right time for long-term…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

1 Marijuana Stock I’d Buy Over Aurora Cannabis

Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio.

Read more »